BRD3 (BD1) Inhibitor Screening Assay Kit

Art Nr.: BPS-32513, BPS
Biomol GmbH
Waidmannstr. 35
Tel:+49-40 - 85 32 600
0800 - 24 66 651 free call
Fax: +49-40 - 85 32 60-22
0800 - 24 66 652 free call

BRD3 (BD1) Inhibitor Screening Assay Kit

Catalog #: BPS-32513
Size: 384 reactions
The BRD3 (BD1) Inhibitor Screening Assay Kit is designed to measure the inhibition of BRD3 bromodomain 1 (BD1) from binding to its substrate. The key to the BRD3 (BD1) Inhibitor Screening Assay Kit is the highly specific binding of the BRD3 bromodomain 1 to the acetylated histone substrate. With this kit, only three simple steps on a microtiter plate are required. First, a sample containing BRD3 bromodomain 1 and an inhibitor of choice is incubated with the biotinylated substrate for thirty minutes. Next, acceptor beads are added, then donor beads, followed by reading the Alpha-counts.
BRD3, RING3L, Bromodomain
Supplied As:
Kit comes in a convenient AlphaLISA® format, with biotinylated histone peptide substrate, assay buffer, detection buffer and purified, GST-tagged BRD3 BD1 to perform a total of 384 enzyme reactions.

DMSO above 0.5%. Only limited amounts of DMSO can be included, as it has been shown to disrupt BRD-ligand interaction. Avoid green and blue dyes that absorb light in the Alphascreen® signal emission range (520-620 nm), such as Trypan Blue. Avoid the use of the potent singlet oxygen quenchers such as sodium azide (NaN3) or metal ions (Fe2+, Fe3+, Cu2+, Zn2+ and Ni2+). The presence of >1% RPMI 1640 culture medium leads to a signal reduction due to the presence of excess biotin and iron in this medium. MEM, which lacks these components, does not affect Alphascreen® assays.

Instructions for use:
See assay kit data sheet for detailed protocol.
Storage / Stability:

At least 12 months from date of receipt, when stored as directed. Kit components require different storage conditions. Be sure to store each component at the proper temperature upon arrival.

Useful for the study of bromodomain binding assays, screening bromodomain inhibitors and selectivity profiling.
Muller S, Filippakopoulos P, Knapp S. Expert Rev Mol Med. 2011 Sep 13;13:e29.